The African continent is striving to significantly boost its local vaccine production, with a goal of reaching 60% by 2040. Currently, the region produces only 1% of its vaccines locally. This ambitious target was highlighted by Amadou Sall, Executive Director of the Coalition for Epidemic Preparedness Innovations (CEPI), during an interview with the Agence Nigérienne de Presse. Sall emphasized that achieving this goal will require substantial investments in research, infrastructure, and skilled personnel.
The second edition of the Dakhla Global Summit, held in Morocco, brought together international stakeholders to discuss pressing health issues. The summit, organized by the Mohammed VI Foundation for Science and Health and the African Academy of Health Sciences, focused on "Health, Social Protection, and Human Development." The event aimed to foster collaborations between public institutions, universities, hospitals, research organizations, and African development partners. Sall's participation underscored the importance of cooperation in advancing Africa's pharmaceutical industry.
To transition from nascent vaccine production to a competitive and sustainable pharmaceutical industry, Africa must establish a comprehensive ecosystem. This involves developing research capabilities, building infrastructure, and cultivating a skilled workforce. Regulatory frameworks and market access are also crucial components. Sall noted that several countries, including Senegal, Morocco, Egypt, Rwanda, and South Africa, have demonstrated political will in these areas, which is a positive step forward.
The African Center for Disease Control and Prevention (Africa CDC) and the World Health Organization (WHO) are playing key roles in supporting the development of the pharmaceutical industry. Sall highlighted the need for adapted regulations, investments, and competencies to drive growth. Furthermore, he stressed the importance of opening up African markets to facilitate the development of the industry. This will enable the continent to capitalize on its investments and create a sustainable pharmaceutical sector.
International cooperation, particularly among African countries, is essential for building a robust pharmaceutical industry. Sall emphasized that promoting the purchase of medical products manufactured in Africa is vital. This cooperation will help create a vibrant market for locally produced vaccines and medicines. The Africa CDC and WHO are well-positioned to facilitate this cooperation and provide technical assistance to countries.
The Dakhla Global Summit provided a platform for stakeholders to engage in meaningful discussions about Africa's health challenges. The event highlighted the need for collaborative efforts to address these challenges and create a more sustainable future for the continent. As the pharmaceutical industry continues to evolve, Africa's ability to produce its own vaccines and medicines will be critical in ensuring access to life-saving treatments.
The goal of producing 60% of vaccines locally by 2040 is ambitious, but achievable with concerted efforts from governments, international organizations, and industry stakeholders. As Sall noted, this requires a multifaceted approach that addresses research, infrastructure, and regulatory frameworks. With commitment and cooperation, Africa can make significant strides in developing a competitive and sustainable pharmaceutical industry that serves the needs of its populations.
Key points
- Africa aims to increase local vaccine production from 1% to 60% by 2040.
- Establishing a comprehensive ecosystem with research, infrastructure, and skilled personnel is crucial.
- International cooperation, particularly among African countries, is essential for building a robust pharmaceutical industry.
Reporting sources
- Industrie pharmaceutique africaine : seulement 1 % de production locale pour un objectif de 60 % d’ici 2040 (expert) · Agence Nigérienne de Presse